logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience picks up new patent for DehydraTECH drug delivery technology

The new patent brings the biotechnology company's total to 16 across the US and Australia

cannabis pills
DehydraTECH increases effectiveness and speed of onset of cannabinoids

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) announced Tuesday that it has been granted a new patent in Australia to protect its proprietary drug delivery platform.

The Kelowna, BC-based company is pioneering its DehydraTECH technology, which changes the way that active pharmaceutical ingredients enter the bloodstream to promote healthier methods of ingestion and increase overall effectiveness.

The new patent covers ready-to-drink beverage compositions, a complement to its already-awarded patent for orally ingestible configurations.

READ: Lexaria Bioscience picks up patents in the US and Australia for its DehydraTECH technology

The biotech company told investors that the new patents are the first to be granted in Lexaria’s second and third patent families outside of its original patents for food and beverage compositions infused with lipophilic active agents and methods of use thereof, under which 14 existing patents were previously granted.

The two new patents, granted August 15, are the first to cover active pharmaceutical applications to deliver cannabinoid treatment methods for a wide range of conditions such as heart disease, mental health and diabetes.

According to Lexaria, claims granted under the two new patent families protect DehydraTECH’s various delivery methods including dry beverages, energy drinks, flavoured water and carbonated beverages, to name a few.

The protection also extends to food and pharmaceutical compositions like pills, gels and liquids.

Lexaria now has 16 patents awarded in the US and Australia to cover DehydraTECH, with 60 applications still pending.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Lexaria Bioscience Corp.

Price: 0.54 CAD

CSE:LXX
Market: CSE
Market Cap: $43.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

on 01/22/2020

2 min read